rs397507986

Positions:

• chr13-32370503-TGGA-T

Variant summary

Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2 PM4_Supporting

The NM_000059.4(BRCA2):​c.8437_8439delGGA​(p.Gly2813del) variant causes a conservative inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★★).

• Frequency: Genomes: not found (cov: 32)
• Consequence: BRCA2 NM_000059.4 conservative_inframe_deletion
• Clinical Significance: Uncertain significance criteria provided, multiple submitters, no conflicts U:6 O:1
• Conservation: PhyloP100: 9.92

Genes affected

BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

BRCA2 (HGNC:):

ACMG classification

Verdict is Uncertain_significance. Variant got 3 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PM4: Nonframeshift variant in NON repetitive region in NM_000059.4. Strenght limited to Supporting due to length of the change: 1aa.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
BRCA2	NM_000059.4	c.8437_8439delGGA	p.Gly2813del	conservative_inframe_deletion	19/27	ENST00000380152.8	NP_000050.3

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
BRCA2	ENST00000380152.8	c.8437_8439delGGA	p.Gly2813del	conservative_inframe_deletion	19/27	5	NM_000059.4	ENSP00000369497.3
BRCA2	ENST00000530893.7	c.8068_8070delGGA	p.Gly2690del	conservative_inframe_deletion	19/27	1		ENSP00000499438.2
BRCA2	ENST00000614259.2	n.*495_*497delGGA		non_coding_transcript_exon_variant	18/26	2		ENSP00000506251.1
BRCA2	ENST00000614259	n.*495_*497delGGA		3_prime_UTR_variant	18/25	2		ENSP00000506251.1

Frequencies

GnomAD3 genomes Cov.: 32

We have no GnomAD4 exomes data on this position. Probably position not covered by the project.

GnomAD4 genome Cov.: 32

Bravo AF: 0.00000378

ClinVar

Significance: Uncertain significance

Submissions summary: Uncertain:6 Other:1

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not provided Uncertain:2

Uncertain significance, criteria provided, single submitter	clinical testing	Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	Nov 09, 2021	The p.Gly2813del variant in BRCA2 has been reported in 3 individuals with breast or ovarian cancer and segregated with disease in 1 affected relative (Kim 2006 PMID: 16949048, Choi 2015 PMID: 26402875, Gao 2020 PMID: 31825140). It was absent from large population studies. This variant has also been reported in ClinVar (Variation ID 52588). This variant is a deletion of 1 amino acid at position 2813 and is not predicted to alter the protein reading-frame. It is unclear if this deletion will impact the protein. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Supporting, PM2_Supporting, PM4_Supporting. -
Uncertain significance, criteria provided, single submitter	clinical testing	Quest Diagnostics Nichols Institute San Juan Capistrano	Sep 14, 2023	In the published literature, this variant has been reported in individuals with breast cancer (PMID: 34645131 (2022), 16949048 (2006)) and ovarian cancer (PMID: 26402875 (2015)). This variant has also been reported in an unaffected individual (PMID: 32467295 (2020)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, we are unable to determine the clinical significance of this variant. -

Hereditary cancer-predisposing syndrome Uncertain:2

Uncertain significance, criteria provided, single submitter	clinical testing	Ambry Genetics	Sep 30, 2023	The c.8437_8439delGGA variant (also known as p.G2813del) is located in coding exon 18 of the BRCA2 gene. This variant results from an in-frame GGA deletion at nucleotide positions 8437 to 8439. This results in the in-frame deletion of a glycine at codon 2813. This alteration has been identified in individuals diagnosed with breast and/or ovarian cancer (Han SH et al. Clin Genet, 2006 Dec;70:496-501; Kim BY et al. Biochem Biophys Res Commun, 2006 Oct;349:604-10; Choi MC et al. Int J Gynecol Cancer, 2018 Feb;28:308-315). Of note, this alteration is also known as 8662delGGA in published literature. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Uncertain significance, criteria provided, single submitter	clinical testing	Color Diagnostics, LLC DBA Color Health	Feb 21, 2023	This variant causes an in-frame deletion of one amino acid in the DNA-binding domain of the BRCA2 protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast or ovarian cancer (PMID: 29240602, 34645131). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

Malignant tumor of breast Uncertain:1

Uncertain significance, no assertion criteria provided

clinical testing

Department of Pathology and Laboratory Medicine, Sinai Health System

-

The BRCA2 p.Gly2813del variant was identified in 2 of 2180 proband chromosomes (frequency: 0.001) from individuals or families with breast or ovarian cancer and was not identified in 334 control chromosomes from healthy individuals (Kim 2006, Choi 2018). The variant was also identified in dbSNP (ID: rs397507986, as “With untested allele”), in ClinVar (clinical significance not provided), and ARUP Laboratories (as Definitely pathogenic) databases. The variant was not identified in GeneInsight-COGR, Clinvitae, Cosmic, LOVD 3.0, UMD-LSDB, BIC Database, or Zhejiang University Database. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). One study identified the variant in a Korean patient with ovarian cancer as well as in her sister who had breast cancer demonstrating co-segregation of the variant albeit only in 2 family members tested (Choi 2018). This variant is an in-frame deletion resulting in the removal of a glycine (gly) residue at codon 2813; the impact of this alteration on BRCA2 protein function is not known. Although in silico protein prediction algorithms are not designed to predict the functioneffect of in-frame deletions the p.Gly2813 reside is well conserved across many species. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -

Hereditary breast ovarian cancer syndrome Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Labcorp Genetics (formerly Invitae), Labcorp

Nov 08, 2023

This variant, c.8437_8439del, results in the deletion of 1 amino acid(s) of the BRCA2 protein (p.Gly2813del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features consistent with hereditary breast and ovarian cancer syndrome (PMID: 16949048, 26402875, 29240602, 34645131). This variant is also known as 8665_8667delGGA; c.8662delGGA. ClinVar contains an entry for this variant (Variation ID: 52588). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Familial cancer of breast Other:1

not provided, no classification provided

literature only

ClinVar Staff, National Center for Biotechnology Information (NCBI)

-

- -

Computational scores

Source: dbNSFP v4.3

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.010		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs397507986; hg19: chr13-32944640;